Antibe Therapeutics Inc. (TSX: ATE)
Canada
· Delayed Price · Currency is CAD | Market Cap | 15.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.55M |
| Shares Out | 52.65M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | 1.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.260 |
| Previous Close | 0.295 |
| Day's Range | 0.260 - 0.350 |
| 52-Week Range | 0.150 - 1.230 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | 4.74 (+1,506.78%) |
| Earnings Date | Feb 19, 2024 |
About Antibe Therapeutics
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pai... [Read more]
Financial Performance
Financial StatementsNews
Antibe Announces Appointment of Receiver
TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Cre...
Antibe Announces Appointment of Receiver
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Announces Appointment of Receiver.
Antibe Provides Update on CCAA Proceedings
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Provides Update on CCAA Proceedings.
Antibe Announces TSX Delisting Review
TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securit...
Antibe Announces Granting of Initial Order Under Companies’ Creditors Arrangement Act
TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies’ Creditors Arrangem...
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Announces Granting of Initial Order under Companies' Creditors Arrangement Act.
Antibe to File an Application for an Initial Order Under Companies’ Creditors Arrangement Act
TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial Li...
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe to File an Application for an Initial Order under Companies' Creditors Arrangement Act.
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE ANNOUNCES FDA CLINICAL HOLD ON OTENAPROXESUL AND LEGAL ACTION BY NUANCE.
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE TO PRESENT OTENAPROXESUL PK/PD RESULTS AT THE ASRA PAIN MEDICINE MEETING.
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE TO PRESENT OTENAPROXESUL PK/PD RESULTS AT THE AMERICAN ACADEMY OF PAIN MEDICINE MEETING.
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma.
Antibe Therapeutics Non-GAAP EPS of -C$0.08
Antibe Reports Q3 2024 Interim Financial and Operating Results
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE REPORTS Q3 2024 INTERIM FINANCIAL AND OPERATING RESULTS.
Antibe Extends Early Warrant Exercise Incentive Program
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Extends Early Warrant Exercise Incentive Program.
Antibe Announces Early Warrant Exercise Incentive Program
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Announces Early Warrant Exercise Incentive Program.
Antibe Therapeutics Announces Amendment to Warrant Terms
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Announces Amendment to Warrant Terms.
Antibe Therapeutics reports Q2 results
Antibe Therapeutics reports Q2 GAAP EPS of -C$0.10. The company had a cash balance of C$27.9M as of Sep. 30.
Antibe Reports Q2 2024 Interim Financial and Operating Results
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE REPORTS Q2 2024 INTERIM FINANCIAL AND OPERATING RESULTS.
Antibe Reports PK Results of First Clinical Study of Otenaproxesul's New Formulation
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE REPORTS PK RESULTS OF FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION.
Antibe Completes First Clinical Study of Otenaproxesul's New Formulation
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE COMPLETES FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION.
Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE INITIATES FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION.
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul.
Antibe Announces Results of 2023 Annual Meeting
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE ANNOUNCES RESULTS OF 2023 ANNUAL MEETING.
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
TORONTO , Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group. The View Fr...